Armenia - angielski - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

haupt pharma muenster gmbh - letrozole - tablets film-coated - 2,5mg

Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

aspen pharma trading ltd - estriol - vaginal cream - 1mg/1gram

Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - estriol - vaginal cream - 1mg/1gram

Australia - angielski - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch; sodium starch glycollate type a; colloidal anhydrous silica; hypromellose; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; macrogol 400 - indicated for the treatment of post menopausal women with hormone receptor positive breast cancer. . the safety and efficacy of neoadjuvant use of letrozole has not been established. letrozole is not indicated in hormone receptor negative disease.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; sodium starch glycollate; microcrystalline cellulose; hypromellose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; iron oxide yellow; macrogol 400 - for the treatment of postmenopausal women with hormone receptor positive breast cancer (see clinical trials). the safety and efficacy of neoadjuvant use of letrozole has not been established. letrozole is not indicated in hormone receptor negative disease.

Izrael - angielski - Ministry of Health

novartis israel ltd - letrozole - film coated tablets - letrozole 2.5 mg - letrozole - letrozole - femara (letrozole tablets) is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whome hormone receptor status cannot be determined locally advanced or metastatic breast cancer. femara is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; hypromellose; microcrystalline cellulose; titanium dioxide; macrogol 8000; sodium starch glycollate; maize starch; iron oxide yellow; colloidal anhydrous silica; lactose monohydrate; purified talc - for the treatment of postmenopausal women with hormone receptor positive breast cancer (see clinical trials). the safety and efficacy of neoadjuvant use of letrozole has not been established. letrozole is not indicated in hormone receptor negative disease.

Malta - angielski - Medicines Authority

accord healthcare limited - letrozole - film-coated tablet - letrozole 2.5 mg - endocrine therapy

Malta - angielski - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - letrozole - film-coated tablet - letrozole 2.5 mg - endocrine therapy

Malta - angielski - Medicines Authority

galenicum health, s.l.u calle sant gabriel, 50 esplugues de llobregat 08950 barcelona, spain - film-coated tablet - letrozole 2.5 mg - endocrine therapy